<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187912</url>
  </required_header>
  <id_info>
    <org_study_id>1390/2016</org_study_id>
    <nct_id>NCT03187912</nct_id>
  </id_info>
  <brief_title>Accelerated Corneal Cross-linking With Different Riboflavin Solutions</brief_title>
  <official_title>Effect-evaluation of an Accelerated Corneal Cross-linking Protocol With Different Riboflavin Solutions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following the Bunsen-Roscoe law, accelerated cross-linking protocols with higher irradiation
      intensities and shorter irradiation times have been introduced. In addition, new riboflavin
      solutions with HPMC (hydroxylpropyl methylcellulose) instead of dextran found its way into
      CXL-treatment. The aim of this trial is to evaluate clinical outcomes in an accelerated
      corneal collagen cross-linking protocol with different riboflavin solutions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 19, 2016</start_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kmax</measure>
    <time_frame>12 months</time_frame>
    <description>Steepest Keratometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative central stromal depth of the Demarcation Line</measure>
    <time_frame>1 month</time_frame>
    <description>The depth of the Demarcation Line after CXL will be measured one month postoperatively with an AS-OCT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LogMAR</measure>
    <time_frame>12 months</time_frame>
    <description>Visual Acuity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Riboflavin with 20% Dextran</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Riboflavin drops with Dextran</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Riboflavin with HPMC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Riboflavin drops with HPMC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Riboflavin</intervention_name>
    <description>Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively</description>
    <arm_group_label>Riboflavin with 20% Dextran</arm_group_label>
    <arm_group_label>Riboflavin with HPMC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Progressive Keratoconus

          -  Indication for treatment

          -  Preoperative Pachymetry &gt; 400

        Exclusion Criteria:

          -  Pregnancy

          -  Re-CXL

          -  Keratitis

          -  Other visual acuity limiting eye diseases than corneal ectatic diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gerald Schmidinger, Ass.Prof.PDDr</last_name>
    <email>gerald.schmidinger@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Niklas Pircher, MD</last_name>
    <email>niklas.pircher@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna, Department of Ophthalmology</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 15, 2017</study_first_posted>
  <last_update_submitted>June 14, 2017</last_update_submitted>
  <last_update_submitted_qc>June 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Gerald Schmidinger</investigator_full_name>
    <investigator_title>Ass. Prof. PDDr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
    <mesh_term>Dextrans</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

